Acalabrutinib Cas:1420477-60-6
Acalabrutinib(ACP-196) is a selective second-generation BTK inhibitor that inhibits the activation of B-cell surface proto-antibody signaling pathways. It has excellent target specificity and is 323-, 94-, 19-, 9- times more selective for BTK than for other TEC kinase family members such as ITK, TXK, BMK, and TEC. It has no activity against EGFR.
Name: Acalabrutinib
Acalabrutinib Cas:1420477-60-6 is an experimental anticancer drug that is a selective inhibitor of Bruton's tyrosine kinase (BTK). This kinase transmits signals from the B-cell receptor (BCR), so any inherited BTK mutation will result in B-cell immunodeficiency. Therefore, BTK inhibitors targeting B cell signaling have shown great promise for the treatment of chronic lymphocytic leukemia (CLL).
